-
Product Insights
Angiosarcoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Angiosarcoma - Drugs In Development, 2023’, provides an overview of the Angiosarcoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Angiosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Merkel Cell Carcinoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Merkel Cell Carcinoma - Drugs In Development, 2023’, provides an overview of the Merkel Cell Carcinoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Merkel Cell Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Nonmelanomatous Skin Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Nonmelanomatous Skin Cancer - Drugs In Development, 2023’, provides an overview of the Nonmelanomatous Skin Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Nonmelanomatous Skin Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Non-Rhabdomyosarcoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Non-Rhabdomyosarcoma - Drugs In Development, 2023’, provides an overview of the Non-Rhabdomyosarcoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Non-Rhabdomyosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CRD-100 in Angiosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CRD-100 in Angiosarcoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CRD-100 in Angiosarcoma Drug Details: CRD-100 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CRD-100 in Bone Sarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CRD-100 in Bone Sarcoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CRD-100 in Bone Sarcoma Drug Details: CRD-100 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CRD-100 in Fibrosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CRD-100 in Fibrosarcoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CRD-100 in Fibrosarcoma Drug Details: CRD-100 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CRD-100 in Merkel Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CRD-100 in Merkel Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CRD-100 in Merkel Cell Carcinoma Drug Details: CRD-100 is under development...